In Sweden the key to the successful implementation of precision medicine in healthcare has been the bottom-up approach where academia and health-care have joined forces to build a national infrastructure. This work has been de-scribed in a recent publication in Nature Medicine by 42 authors from the Clinical Genomics platform at SciLifeLab and Genomic Medicine Sweden (GMS). CMMer Richard Rosenquist Brandell, the Director of GMS, is the corresponding author.
Early intervention with rituximab, a drug used in the treatment of rheumatoid arthritis, can reduce the risk of deterioration in myasthenia gravis, an autoimmune disease that causes loss of muscle control. This is according to a randomised clinical study led by researchers at Karolinska Institutet and CMM and published in the journal JAMA Neurology.
For CMM L8 building-related emergencies (eg. water leak, CO2) and low temperature freezer issues, please call the Caverion remote center:
010-480 88 08